JUN 26, 2018 7:55 PM PDT

Genomic Markers Identified for Infant Soft Tissue Tumors

WRITTEN BY: Mauri Brueggeman

Epidermal Growth Factor Receptor (EGFR) helps maintain cellular growth and division normally but can become mutated, as in the case with some cancers, so that too many receptors allow exponential, uncontrolled cellular growth and division resulting in a tumor.  EGFR is a transmembrane kinase glycoprotein; its gene locus is found at 7p11.2 and is commonly associated with multiple different cancers as part of gene rearrangements whereby the EGFR signaling pathway becomes deregulated.  EGFR is implicated and/or found in many cancers including lung, breast, head, neck, and colorectal.

B-Raf is another kinase protein associated with processing mitogenic signals between the cell membrane and the nucleus of a cell and its enzymatic activity has been associated with Epidermal Growth Factor and Human Growth Factor ligands.  The gene BRAF is located at 7q34 and is considered a proto-oncogene; there is significant literature outlining the present of mutations and rearrangements involving BRAF resulting in a multitude of cancers including melanoma and colorectal cancer.

A new article from Nature Communications published on June 18, 2018 now outlines a newly discovered connection between multiple different infant soft tissue tumors and these two specific genes.  Childhood tumors, especially those in infancy are often confined to age and developmental stage but little has been known about their etiology and therefore, how to best treat them.  Congenital mesoblastic nephroma (CMN) is renal malignancy in children under 6 months old.  Infantile fibrosarcoma (IFS) is comprised of mutated spindle fiber cells often in the soft tissues of the extremities or abdominal region in an infant.  The researchers examined similar soft tissue tumors for the presence of EGFR or BRAF rearrangement as a diagnostic marker and found that in all CMN specimens evaluated, there was a single in-frame internal tandem duplication (ITD) within the EGFR domain.  The EGFR-ITD was not observed in other tumor types like glioma or adenocarcinoma of the lung.  Additionally, the group discovered mutations in the BRAF gene in some CMN cases also.  A mutated fusion protein as a result of BRAF rearrangement has been observed in some IFS patients but has not been seen in CMN. 

Genomic findings can be groundbreaking for the course of cancer treatments used and for the future development of novel treatments; basing clinical and therapeutic decisions on the mutations present, rather than on the phenotypic findings, is changing the practice of oncology.  For infants with CMN and EGFR-ITD, already existing treatments are available which target EGFR mutations previously identified in other cancers.  This is also true for IFS where a BRAF mutation is the driver.

Sources: Nature Communications, Oncology Reports, Wellcome Sanger Institute, American Society of Clinical Oncology, Expert Opinion on Therapeutic Targets,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 10, 2020
Cardiology
Liposomal Delivery Could Help Prevent Doxorubicin Cardiotoxicity
NOV 10, 2020
Liposomal Delivery Could Help Prevent Doxorubicin Cardiotoxicity
One of the greatest failures of modern cancer therapies is the rather substantial off-target toxic effects many radio-, ...
NOV 16, 2020
Cancer
Fingerprinting Ginger Extracts and Testing Their Anti-Cancer Abilities
NOV 16, 2020
Fingerprinting Ginger Extracts and Testing Their Anti-Cancer Abilities
Modern medicine relies on careful study and isolation of compounds or proteins, but many studies point to natural herbal ...
DEC 09, 2020
Cancer
Fertility after breast cancer
DEC 09, 2020
Fertility after breast cancer
New data presented at the 2020 San Antonio Breast Cancer Symposium this week dives into the complexities of fertility af ...
DEC 23, 2020
Cancer
A Combination of Photo and Sonodynamic Therapies Could Assist in Treating Brain Cancer
DEC 23, 2020
A Combination of Photo and Sonodynamic Therapies Could Assist in Treating Brain Cancer
Brain cancer is an incredible challenge for modern medicine. Most drugs don’t make it past the blood-brain barrier ...
JAN 12, 2021
Cancer
The frightening association between oral sex and HPV-related cancers
JAN 12, 2021
The frightening association between oral sex and HPV-related cancers
New research published recently in the online edition of CANCER, a peer-reviewed journal of the American Cancer Soc ...
JAN 24, 2021
Cancer
Decoding the "why" of the Warburg effect
JAN 24, 2021
Decoding the "why" of the Warburg effect
New research led by immunologist Ming Li from Sloan Kettering Institute unpacks a century-old mystery of cancer: why can ...
Loading Comments...